OVERALL SURVIVAL IN POST-MENOPAUSAL WOMEN WITH HR+/HER2-ADVANCED BREAST CANCER RECEIVING A CDK 4 AND 6 INHIBITOR plus FULVESTRANT AFTER PROGRESSING ON/AFTER PRIOR ENDOCRINE THERAPY: A FRACTIONAL POLYNOMIAL NETWORK META-ANALYSIS

被引：0
|
作者：
Hirst, A. [1 ]
Davie, A. [2 ]
Carter, Cuyun G. [3 ]
Haddad, N. [3 ]
Traore, S. [2 ]
Brufsky, A. [4 ]
Harbeck, N. [5 ]
Pivot, X. [6 ]
机构：
[1] ICON PLC, London, England
[2] Eli Lilly & Co Ltd, Windlesham, Surrey, England
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[5] Univ Munchen LMU, Brustzentrum, Munich, Germany
[6] Paul Strauss Canc Ctr, Strasbourg, France
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN4
引用
收藏
页码：S421 / S421
页数：1
相关论文
共 50 条
  • [1] Abemaciclib plus fulvestrant in East Asian women with HR+, HER2-advanced breast cancer: Overall survival from MONARCH 2
    Huang, C-S.
    Toi, M.
    Im, Y-H.
    Iwata, H.
    Sohn, J.
    Wang, H-C.
    Masuda, N.
    Im, S-A.
    Lu, Y.
    Haddad, N.
    Sakaguchi, S.
    Hurt, K.
    Neven, P.
    Llombart-Cussac, A.
    Sledge, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S1258 - S1259
  • [2] Abemaciclib plus fulvestrant in East Asian women with HR+, HER2-advanced breast cancer: Overall survival from MONARCH 2
    Toi, Masakazu
    Huang, Chiun-Sheng
    Im, Young-Hyuck
    Sohn, Joohyuk
    Zhang, Wei
    Sakaguchi, Sachi
    Haddad, Nadine
    van Hal, Gertjan
    Sledge Jr, George W.
    CANCER SCIENCE, 2023, 114 (01) : 221 - 226
  • [3] NETWORK META-ANALYSIS COMPARING PALBOCICLIB PLUS FULVESTRANT WITH EVEROLIMUS PLUS EXEMESTANE FOR HR+/HER2-ADVANCED BREAST CANCER THAT HAS BECOME RESISTANT TO PREVIOUS ENDOCRINE THERAPY
    LeReun, C.
    Gentilini, A.
    Large, S.
    Chowdhury, M.
    Smith, A.
    Rinciog, C.
    VALUE IN HEALTH, 2019, 22 : S446 - S446
  • [4] CDK4/6 inhibitors plus endocrine therapy improve overall survival in advanced HR+/HER2-breast cancer: A meta-analysis of randomized controlled trials
    Wang, Liquan
    Gao, Shuyan
    Li, Dianfang
    Ran, Xuehong
    Sheng, Zhixin
    Wu, Wei
    Yang, Xiaojing
    BREAST JOURNAL, 2020, 26 (07): : 1439 - 1443
  • [5] Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2-advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.
    Kalinsky, Kevin
    Bianchini, Giampaolo
    Hamilton, Erika P.
    Graff, Stephanie L.
    Park, Kyong Hwa
    Jeselsohn, Rinath
    Demirci, Umut
    Martin, Miguel
    Layman, Rachel M.
    Hurvitz, Sara A.
    Sammons, Sarah L.
    Kaufman, Peter A.
    Munoz, Montserrat
    Tseng, Ling-Ming
    Knoderer, Holly
    Nguyen, Bastien
    Zhou, Yanhong
    Ravenberg, Elizabeth
    Litchfield, Lacey M.
    Wander, Seth Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA1001 - LBA1001
  • [6] CDK4/6 inhibitors plus endocrine therapy vs. placebo plus endocrine therapy for HR+/HER2-advanced breast cancer: a phase III RCTs based meta-analysis
    Luo, Cailu
    Yu, Kunlin
    Luo, Xiaodan
    Lian, Tao
    Liu, Xuejuan
    Xu, Wang
    Jin, Zhongkui
    BMC CANCER, 2024, 24 (01)
  • [7] STEPAUT: Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2-advanced breast cancer progressing on/after prior endocrine therapy, in routine clinical practice
    Steger, G.
    Hubalek, M.
    Pfeiler, G.
    Greil, R.
    Ohler, L.
    Helfgott, R.
    Petru, E.
    Mraz, B.
    Hennebelle, M.
    Winiger, I.
    Gnant, M.
    EUROPEAN JOURNAL OF CANCER, 2016, 57 : S104 - S105
  • [8] MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
    Sledge, George W., Jr.
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joohyuk
    Inoue, Kenichi
    Pivot, Xavier
    Burdaeva, Olga
    Okera, Meena
    Masuda, Norikazu
    Kaufman, Peter A.
    Koh, Han
    Grischke, Eva-Maria
    Frenzel, Martin
    Lin, Yong
    Barriga, Susana
    Smith, Ian C.
    Bourayou, Nawel
    Llombart-Cussac, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (25) : 2875 - +
  • [9] First-line CDK4/6 inhibitor-based combinations for HR+/HER2-advanced breast cancer: A Bayesian network meta-analysis
    Guo, Xianan
    Zhou, Yunxiang
    Zhang, Kun
    Lu, Wei
    Zhong, Xi
    Wu, Shijie
    Shen, Lu
    Chen, Huihui
    Chen, Yiding
    JOURNAL OF EVIDENCE BASED MEDICINE, 2024, 17 (01) : 106 - 118
  • [10] Bireociclib plus fulvestrant for advanced HR+/HER2- breast cancer progressing after endocrine therapy: Interim analysis of a phase 3 trial (BRIGHT-2)
    Wang, Jiayu
    Zhang, Qingyuan
    Li, Huiping
    Tong, Zhongsheng
    Ouyang, Quchang
    Li, Huihui
    Teng, Yuee
    Wang, Biyun
    Sun, Tao
    Wang, Jingfen
    Li, Wei
    Niu, Zhaofeng
    Li, Hongsheng
    Gong, Chang
    Wang, Li
    Liu, Fei
    Wang, Shuya
    Meng, Yaping
    Duan, Xianghui
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345